What is a stock summary page? Click here for an overview.
Business Description
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US10806X1028
Compare
Compare
Traded in other countries / regions
BBIO.USA2CL.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-06-27Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | -1.6 | |||||
| Debt-to-Equity | -1.18 | |||||
| Debt-to-EBITDA | -3.96 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -3.77 | |||||
| Beneish M-Score | 17.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.2 | |||||
| 3-Year EBITDA Growth Rate | 14.1 | |||||
| 3-Year EPS without NRI Growth Rate | 4.1 | |||||
| 3-Year FCF Growth Rate | 9.1 | |||||
| 3-Year Book Growth Rate | -9.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 41.78 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 68.99 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.33 | |||||
| 9-Day RSI | 37.49 | |||||
| 14-Day RSI | 42.33 | |||||
| 3-1 Month Momentum % | 14.81 | |||||
| 6-1 Month Momentum % | 20.55 | |||||
| 12-1 Month Momentum % | 12.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.67 | |||||
| Quick Ratio | 4.67 | |||||
| Cash Ratio | 4.41 | |||||
| Days Sales Outstanding | 5.32 | |||||
| Days Payable | 1063.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 | |||||
| Shareholder Yield % | -4.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.25 | |||||
| Operating Margin % | -260.19 | |||||
| Net Margin % | -241.44 | |||||
| FCF Margin % | -238.68 | |||||
| ROA % | -70.97 | |||||
| ROIC % | -234.84 | |||||
| 3-Year ROIIC % | -1.77 | |||||
| ROC (Joel Greenblatt) % | -1337.61 | |||||
| ROCE % | -72.34 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 26.18 | |||||
| EV-to-EBIT | -16.39 | |||||
| EV-to-Forward-EBIT | -10.64 | |||||
| EV-to-EBITDA | -16.62 | |||||
| EV-to-Forward-EBITDA | -10.94 | |||||
| EV-to-Revenue | 32.71 | |||||
| EV-to-Forward-Revenue | 40.8 | |||||
| EV-to-FCF | -13.7 | |||||
| Price-to-GF-Value | 1.11 | |||||
| Earnings Yield (Greenblatt) % | -6.1 | |||||
| FCF Yield % | -8.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BridgeBio Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 221.902 | ||
| EPS (TTM) ($) | -2.85 | ||
| Beta | 1.25 | ||
| 3-Year Sharpe Ratio | 0.88 | ||
| 3-Year Sortino Ratio | 2.48 | ||
| Volatility % | 41.95 | ||
| 14-Day RSI | 42.33 | ||
| 14-Day ATR ($) | 1.975106 | ||
| 20-Day SMA ($) | 33.83425 | ||
| 12-1 Month Momentum % | 12.03 | ||
| 52-Week Range ($) | 21.62 - 39.47 | ||
| Shares Outstanding (Mil) | 190.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BridgeBio Pharma Inc Frequently Asked Questions
What is BridgeBio Pharma Inc(BBIO)'s stock price today?
The current price of BBIO is $32.31. The 52 week high of BBIO is $39.47 and 52 week low is $21.62.
When is next earnings date of BridgeBio Pharma Inc(BBIO)?
The next earnings date of BridgeBio Pharma Inc(BBIO) is 2025-05-02 Est..
Does BridgeBio Pharma Inc(BBIO) pay dividends? If so, how much?
BridgeBio Pharma Inc(BBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers